{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:50:00Z","timestamp":1786445400889,"version":"build-2736575974"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc","award":["G0505124"],"award-info":[{"award-number":["G0505124"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Clostridioides difficile infection (CDI) is a common healthcare-associated infection with limited treatment options. Omadacycline, an aminomethylcycline tetracycline, has potent in vitro activity against C difficile and a low propensity to cause CDI in clinical trials. We aimed to assess fecal pharmacokinetics and gut microbiome effects of oral omadacycline compared to oral vancomycin in healthy adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a phase 1, nonblinded, randomized clinical trial conducted in healthy volunteers aged 18\u201340 years. Subjects received a 10-day course of omadacycline or vancomycin. Stool samples were collected at baseline, daily during therapy, and at follow-up visits. Omadacycline and vancomycin stool concentrations were assessed, and microbiome changes were compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixteen healthy volunteers with a mean age of 26 (standard deviation [SD], 5) years were enrolled; 62.5% were male, and participants\u2019 mean body mass index was 23.5 (SD, 4.0) kg\/m2. Omadacycline was well tolerated with no safety signal differences between the 2 antibiotics. A rapid initial increase in fecal concentrations of omadacycline was observed compared to vancomycin, with maximum concentrations achieved within 48 hours. A significant difference in alpha diversity was observed following therapy in both the omadacycline and vancomycin groups (P &amp;lt; .05). Bacterial abundance and beta diversity analysis showed differing microbiome changes in subjects who received omadacycline versus vancomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Subjects given omadacycline had high fecal concentrations with a distinct microbiome profile compared to vancomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT06030219.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad537","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T17:58:50Z","timestamp":1701799130000},"page":"273-281","source":"Crossref","is-referenced-by-count":14,"title":["Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers"],"prefix":"10.1093","volume":"229","author":[{"given":"Jinhee","family":"Jo","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshida","family":"Begum","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh M","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Agyapong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake M","family":"Hanson","sequence":"additional","affiliation":[{"name":"UTHealth Houston School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossaena","family":"Ayele","sequence":"additional","affiliation":[{"name":"UTHealth Houston School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Lancaster","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jahangir Alam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J","family":"Gonzales-Luna","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-7503","authenticated-orcid":false,"given":"Kevin W","family":"Garey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research College of Pharmacy, University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"2024011216393226600_jiad537-B1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"key":"2024011216393226600_jiad537-B2","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1371\/journal.pbio.0060280","article-title":"The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing","volume":"6","author":"Dethlefsen","year":"2008","journal-title":"PLoS Biol"},{"key":"2024011216393226600_jiad537-B3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.05496-11","article-title":"Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile\u2013induced colitis","volume":"80","author":"Buffie","year":"2012","journal-title":"Infect Immun"},{"key":"2024011216393226600_jiad537-B4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/MIB.0000000000000750","article-title":"Current understanding of dysbiosis in disease in human and animal models","volume":"22","author":"DeGruttola","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2024011216393226600_jiad537-B5","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/ncomms4114","article-title":"Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection","volume":"5","author":"Theriot","year":"2014","journal-title":"Nat Commun"},{"key":"2024011216393226600_jiad537-B6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/ciab718","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024011216393226600_jiad537-B7","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/cid\/ciaa484","article-title":"Impact of revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America clinical practice guidelines on the treatment of Clostridium difficile infections in the United States","volume":"72","author":"Clancy","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024011216393226600_jiad537-B8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkw383","article-title":"Short- and long-term effects of oral vancomycin on the human intestinal microbiota","volume":"72","author":"Isaac","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024011216393226600_jiad537-B9","doi-asserted-by":"crossref","first-page":"e0144021","DOI":"10.1128\/Spectrum.01440-21","article-title":"In vitro activity of omadacycline and five comparators against contemporary ribotypes of Clostridioides difficile in Stockholm, Sweden","volume":"9","author":"Camporeale","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2024011216393226600_jiad537-B10","doi-asserted-by":"crossref","first-page":"e00522","DOI":"10.1128\/AAC.00522-20","article-title":"In vitro activity of omadacycline, a new tetracycline analog, and comparators against Clostridioides difficile","volume":"64","author":"Begum","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011216393226600_jiad537-B11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jgar.2022.04.019","article-title":"Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea","volume":"30","author":"Leahy","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2024011216393226600_jiad537-B12","doi-asserted-by":"crossref","first-page":"e01581","DOI":"10.1128\/AAC.01581-18","article-title":"Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial, and distal human colon","volume":"63","author":"Moura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011216393226600_jiad537-B13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/10600280221089007","article-title":"Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence","volume":"57","author":"Garey","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2024011216393226600_jiad537-B14","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1128\/AEM.66.10.4571-4574.2000","article-title":"A PCR assay to discriminate human and ruminant feces on the basis of host differences in Bacteroides-Prevotella genes encoding 16S rRNA","volume":"66","author":"Bernhard","year":"2000","journal-title":"Appl Environ Microb"},{"issue":"Suppl 2","key":"2024011216393226600_jiad537-B15","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024011216393226600_jiad537-B16","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AEM.68.11.5445-5451.2002","article-title":"Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces","volume":"68","author":"Matsuki","year":"2002","journal-title":"Appl Environ Microb"},{"key":"2024011216393226600_jiad537-B17","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1128\/AEM.70.6.3575-3581.2004","article-title":"Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota","volume":"70","author":"Bartosch","year":"2004","journal-title":"Appl Environ Microb"},{"key":"2024011216393226600_jiad537-B18","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1128\/AEM.01043-13","article-title":"Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform","volume":"79","author":"Kozich","year":"2013","journal-title":"Appl Environ Microb"},{"key":"2024011216393226600_jiad537-B19","doi-asserted-by":"crossref","first-page":"e0168821","DOI":"10.1128\/spectrum.01688-21","article-title":"A vancomycin HPLC assay for use in gut microbiome research","volume":"10","author":"Hu","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2024011216393226600_jiad537-B20","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2022"},{"issue":"Suppl 2","key":"2024011216393226600_jiad537-B21","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024011216393226600_jiad537-B22","doi-asserted-by":"crossref","first-page":"102387","DOI":"10.1016\/j.anaerobe.2021.102387","article-title":"Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation","volume":"70","author":"Gonzales-Luna","year":"2021","journal-title":"Anaerobe"},{"key":"2024011216393226600_jiad537-B23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkz513","article-title":"Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates","volume":"75","author":"Shen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024011216393226600_jiad537-B24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciaa912","article-title":"Emergence of clinical Clostridioides difficile isolates with decreased susceptibility to vancomycin","volume":"74","author":"Darkoh","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024011216393226600_jiad537-B25","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/jac\/dkaa118","article-title":"Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017","volume":"75","author":"Karlowsky","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"2024011216393226600_jiad537-B26","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/ciz309","article-title":"Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline","volume":"69","author":"Rodvold","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024011216393226600_jiad537-B27","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1093\/jac\/dkaa364","article-title":"A randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects","volume":"75","author":"Garey","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024011216393226600_jiad537-B28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2024011216393226600_jiad537-B29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/23.1.167","article-title":"Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile","volume":"23","author":"Baird","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"2024011216393226600_jiad537-B30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"2024011216393226600_jiad537-B31","doi-asserted-by":"crossref","first-page":"e01784-16","DOI":"10.1128\/AAC.01784-16","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011216393226600_jiad537-B32","doi-asserted-by":"crossref","first-page":"e76269","DOI":"10.1371\/journal.pone.0076269","article-title":"Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole","volume":"8","author":"Abujamel","year":"2013","journal-title":"PLoS One"},{"key":"2024011216393226600_jiad537-B33","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2217\/fmb-2020-0182","article-title":"Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections","volume":"15","author":"Chopra","year":"2020","journal-title":"Future Microbiol"},{"key":"2024011216393226600_jiad537-B34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrmicro.2016.108","article-title":"Clostridium difficile colitis: pathogenesis and host defence","volume":"14","author":"Abt","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"2024011216393226600_jiad537-B35","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41564-018-0150-6","article-title":"Microbiota-accessible carbohydrates suppress Clostridium difficile infection in a murine model","volume":"3","author":"Hryckowian","year":"2018","journal-title":"Nat Microbiol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad537\/54642019\/jiad537.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/273\/55572087\/jiad537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/1\/273\/55572087\/jiad537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:13:15Z","timestamp":1705083195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/1\/273\/7458919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,5]]},"published-print":{"date-parts":[[2024,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad537","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,15]]},"published":{"date-parts":[[2023,12,5]]}}}